Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors

Molecular Microbiology

Volumn 66, Issue 4, 2007, Pages 1029-1038

  Wang, Huanchen ^a   Yan, Zier ^a   Geng, Jie ^a   Kunz, Stefan ^b   Seebeck, Thomas ^b   Ke, Hengming ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [8 (3 NITROPHENYL)[1,7]NAPHTHYRIDIN 6 YL]BENZOIC ACID; 4 [[3,4 (METHYLENEDIOXY)BENZYL]AMINO] 6 CHLOROQUINAZOLINE; 9 (2 HYDROXY 3 NONYL)ADENINE; ANTILEISHMANIAL AGENT; BAY 60 7550; DIPYRIDAMOLE; ETAZOLATE; GENISTEIN; GLUTAMINE; HESPERETIN; ISOBUTYLMETHYLXANTHINE; L 869298; LUTEOLIN; MK 298; NAPHTHYRIDINE DERIVATIVE; PHENYLALANINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE B1; PHOSPHODIESTERASE INHIBITOR; PROTOZOAL PROTEIN; QUERCETIN; QUINAZOLINE DERIVATIVE; ROLIPRAM; SILDENAFIL; UNCLASSIFIED DRUG; ZAPRINAST; ZARDAVERINE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME STRUCTURE; HUMAN; LEISHMANIA MAJOR; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

1-METHYL-3-ISOBUTYLXANTHINE; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LEISHMANIA MAJOR; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN FOLDING;

LEISHMANIA MAJOR;

EID: 35748936134     PISSN: 0950382X     EISSN: 13652958     Source Type: Journal    
DOI: 10.1111/j.1365-2958.2007.05976.x     Document Type: Article

References (41)

1. Ashutosh, S.S. Goyal, N. (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56 : 143 153.
2. Bender, A.T. Beavo, J.A. (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58 : 488 520.
3. Blokland, A., Schreiber, R. Prickaerts, J. (2006) Improving memory: a role for phosphodiesterases. Curr Pharm Des 12 : 2511 2523.
4. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., et al. (1998) Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Cryst D54 : 905 921.
5. Castro, A., Jerez, M.J., Gil, C. Martinez, A. (2005) Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 25 : 229 244.
6. Conti, M. Beavo, J. (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Ann Rev Biochem 76 : 481 511.
7. Croft, S.L., Seifert, K. Yardley, V. (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123 : 399 410.
8. Desjeux, P. Alvar, J. (2003) Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97 : S3 S15.
9. Galie, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., et al. (2005) Sildenafil use in Pulmonary Arterial Hypertension (SUPER) study group. N Engl J Med 353 : 2148 2157.
10. Houslay, M.D., Schafer, P. Zhang, K.Y. (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10 : 1503 1519.
11. Huai, Q., Liu, Y., Francis, S.H., Corbin, J.D. Ke, H. (2004a) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor IBMX suggest a conformation determinant of inhibitor selectivity. J Biol Chem 279 : 13095 13101.
12. Huai, Q., Wang, H., Zhang, W., Colman, R., Robinson, H. Ke, H. (2004b) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101 : 9624 9629.
13. Iffland, A., Kohls, D., Low, S., Luan, J., Zhang, Y., Kothe, M., et al. (2005) Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system. Biochemistry 44 : 8312 8325.
14. Johner, A., Kunz, S., Linder, M., Shakur, Y. Seebeck, T. (2006) Cyclic nucleotide specific phosphodiesterases of Leishmania major. BMC Microbiol 6 : 25.
15. Jones, T.A., Zou, J.-Y., Cowan, S.W. Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryst A47 : 110 119.
16. Kamhawi, S. (2006) Phlebotomine sand flies and Leishmania parasites: friends or foes? Trends Parasitol 22 : 439 445.
17. Ke, H. Wang, H. (2007) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 7 : 391 403.
18. Kedzierski, L., Zhu, Y. Handman, E. (2006) Leishmania vaccines: progress and problems. Parasitology 133 : S87 S112.
19. Kunz, S., Beavo, J.A., D'Angelo, M.A., Flawia, M.M., Francis, S.H., Johner, A., et al. (2005) Cyclic nucleotide specific phosphodiesterases of the kinetoplastida: a unified nomenclature. Mol Biochem Parasitol 145 : 133 135.
20. Laxman, S., Rascon, A. Beavo, J.A. (2005) Trypanosome cyclic nucleotide phosphodiesterase 2B binds cAMP through its GAF-A domain. J Biol Chem 280 : 3771 3779.
21. Lerner, A. Epstein, P.M. (2006) Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393 : 21 41.
22. Lipworth, B.J. (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 : 167 175.
23. Loiseau, P.M. Bories, C. (2006) Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators. Curr Top Med Chem 6 : 539 550.
24. Lugnier, C. (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109 : 366 398.
25. Menniti, F.S., Faraci, W.S. Schmidt, C.J. (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5 : 660 670.
26. Mishra, J., Saxena, A. Singh, S. (2007) Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 14 : 1153 1169.
27. Navaza, J. Saludjian, P. (1997) AMoRe: an automated molecular replacement program package. Methods Enzymol 276 : 581 594.
28. Omori, K. Kotera, J. (2007) Overview of PDEs and their regulation. Circ Res 100 : 309 327.
29. Otwinowski, Z. Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276 : 307 326.
30. Peluso, M.R. (2006) Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp Biol Med 231 : 1287 1299.
31. Rascon, A., Viloria, M.E., De-Chiara, L. Dubra, M.E. (2000) Characterization of cyclic AMP phosphodiesterases in Leishmania mexicana and purification of a soluble form. Mol Biochem Parasitol 106 : 283 292.
32. Reithinger, R. Dujardin, J.C. (2007) Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 45 : 21 25.
33. Rotella, D.P. (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1 : 674 682.
34. Salem, M.M. Werbovetz, K.A. (2006) Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr Med Chem 13 : 2571 2598.
35. Scapin, G., Patel, S.B., Chung, C., Varnerin, J.P., Edmondson, S.D., Mastracchio, A. et al. (2004) Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43 : 6091 6100.
36. Schwartz, E., Hatz, C. Blum, J. (2006) New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 6 : 342 349.
37. Wang, H., Liu, Y., Chen, Y., Robinson, H. Ke, H. (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280 : 30949 30955.
38. Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S.H., et al. (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281 : 21469 21479.
39. Wang, H., Liu, Y., Hou, J., Zheng, M., Robinson, H. Ke, H. (2007) Structural insight into substrate specificity of phospodiesterase 10. Proc Natl Acad Sci USA 104 : 5782 5787.
40. Xu, R.X., Hassell, A.M., Vanderwall, D., Lambert, M.H., Holmes, W.D., Luther, M.A., et al. (2000) Atomic structure of PDE4: insight into phosphodiesterase mechanism and specificity. Science 288 : 1822 1825.
41. Zhang, K.Y., Card, G.L., Suzuki, Y., Artis, D.R., Fong, D., Gillette, S., et al. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15 : 279 286.